Fryselager. The assignment is a turnkey contract worth approximately NOK 125 million excluding VAT. - This will be a great project that we have had the pleasure of ...

NBX has also joined Intersect, a membership-based organization for the Cardano blockchain ecosystem. As an Enterprise member, NBX will gain voting rights and the ability to participate in Intersect's ...

Reference is made to the stock exchange release published earlier today, June 20, 2025, concerning the employee share purchase program and share allocation.

extraordinary general meeting to consider a proposal to open an investigation. Notice is given to the shareholders of the Company that an extraordinary general meeting for this purpose will be held on ...

to the exercise of options, this is estimated to be a substantial contract for Soiltech¹. The Frame agreement with Equinor has a duration until June 2026, option periods excluded, potentially 2034 ...

us to enter into a contract. We want to thank KONGSBERG for the confidence shown in us and are looking forward to extending the good partnership into the construction phase," says Group Chief ...

5-12 of the Norwegian Securities Trading Act and the Oslo Rule Book II. To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or ...

first quarter, the company increased its EBITDA guidance for 2025 to NOK 0.95-1.2 billion. Following the implementation of a new policy to pay ...

share capital by reducing the par value of each share from NOK 1.00 to NOK 0.70, (ii) issue a total of 75,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.80 per ...

The acceptance period expires at 16:30 today, 20 June 2025, subject to any extension one or several times up until 15 August 2025. The complete terms and conditions for the Offer, including a ...

Primary insider Stephen Naumann has transferred 207,227 shares to his spouse (a close associate of the primary insider). See the enclosed forms for further details about the transaction. 649730_PDMR ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...